SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kagucia E Wangeci, Ziraba Abdhala K, Nyagwange James, Kutima Bernadette, Kimani Makobu, Akech Donald, Ng'oda Maurine, Sigilai Antipa, Mugo Daisy, Karanja Henry, Gitonga John, Karani Angela, Toroitich Monica, Karia Boniface, Otiende Mark, Njeri Anne, Aman Rashid, Amoth Patrick, Mwangangi Mercy, Kasera Kadondi, Ng'ang'a Wangari, Voller Shirine, Ochola-Oyier Lynette I, Bottomley Christian, Nyaguara Amek, Munywoki Patrick K, Bigogo Godfrey, Maitha Eric, Uyoga Sophie, Gallagher Katherine E, Etyang Anthony O, Barasa Edwine, Mwangangi Joseph, Bejon Philip, Adetifa Ifedayo M O, Warimwe George M, Scott J Anthony G, Agweyu Ambrose
Аннотация
METHODS: We conducted cross-sectional serosurveys among randomly selected, age-stratified samples of Health and Demographic Surveillance System (HDSS) residents in Kilifi and Nairobi. Anti-spike (anti-S) immunoglobulin G (IgG) serostatus was measured using a validated in-house ELISA and antibody concentrations estimated with reference to the WHO International Standard for anti-SARS-CoV-2 immunoglobulin.
RESULTS: HDSS residents were sampled in February-June 2022 (Kilifi HDSS N = 852; Nairobi Urban HDSS N = 851) and in August-December 2022 (N = 850 for both sites). Population-weighted coverage for ≥1 doses of COVID-19 vaccine were 11.1% (9.1-13.2%) among Kilifi HDSS residents by November 2022 and 34.2% (30.7-37.6%) among Nairobi Urban HDSS residents by December 2022. Population-weighted anti-S IgG seroprevalence among Kilifi HDSS residents increased from 69.1% (65.8-72.3%) by May 2022 to 77.4% (74.4-80.2%) by November 2022. Within the Nairobi Urban HDSS, seroprevalence by June 2022 was 88.5% (86.1-90.6%), comparable with seroprevalence by December 2022 (92.2%; 90.2-93.9%). For both surveys, seroprevalence was significantly lower among Kilifi HDSS residents than among Nairobi Urban HDSS residents, as were antibody concentrations (p < 0.001).
CONCLUSION: More than 70% of Kilifi residents and 90% of Nairobi residents were seropositive for anti-S IgG by the end of 2022. There is a potential immunity gap in rural Kenya; implementation of interventions to improve COVID-19 vaccine uptake among sub-groups at increased risk of severe COVID-19 in rural settings is recommended.